Drug Type Recombinant vector vaccine, Prophylactic vaccine |
Synonyms COVID 19 vaccine( Gamaleya National Research Center of Epidemiology and Microbiology), COVID-2019 vaccine (Gamaleya National Research Center of Epidemiology and Microbiology, Gam-COVID-Vac Lyo + [6] |
Target |
Action inhibitors |
Mechanism SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Russia (11 Aug 2020), |
RegulationEmergency Use Authorization (India) |
Start Date01 Oct 2023 |
Start Date01 Oct 2023 |
Start Date01 Mar 2023 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | Russia | 11 Aug 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
SARS-CoV-2 acute respiratory disease | Discovery | - | 08 Mar 2022 | |
Severe Acute Respiratory Syndrome | Discovery | India | 30 Nov 2020 | |
COVID-19 | Discovery | - | 01 Nov 2020 | |
Post Acute COVID 19 Syndrome | Discovery | Belarus | 28 Sep 2020 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | 867 | czrppjdlft(qxiqaaphup) = gsqjnvomhm xwpvtmmggg (eunktoopqh ) View more | - | 01 Jan 2022 | |||
AstraZeneca | czrppjdlft(qxiqaaphup) = ztshlphpfp xwpvtmmggg (eunktoopqh ) | ||||||
Phase 3 | 21,977 | (awzrsvjiyb) = asuwlcxqts sxirfcgrhm (rxffucuxes ) View more | Positive | 20 Feb 2021 | |||
Placebo | (awzrsvjiyb) = lasorqdirr sxirfcgrhm (rxffucuxes ) View more |